The Rise of GLP-1 Medications: When Did They Become Popular?

Last reviewed: May 15, 2026 Last updated: May 15, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Glucagon-like peptide-1 (GLP-1) receptor agonists have become one of the most sought-after medications for weight management in recent years. However, their rise to prominence was not overnight—it involved decades of scientific discovery, regulatory milestones, and real-world evidence of their effectiveness. Understanding this timeline reveals how a class of medications originally designed for blood sugar control revolutionized the weight loss landscape.

GLP-1 Discovery: From Laboratory to Clinical Application

Scientists first identified glucagon-like peptide-1 in 1987 as a naturally occurring hormone in the human intestine. This hormone plays a crucial role in regulating blood sugar levels by stimulating insulin secretion when glucose enters the bloodstream. The discovery opened entirely new possibilities for treating type 2 diabetes, a condition affecting over 37 million Americans according to the CDC.

Early research demonstrated that GLP-1 not only improved glucose control but also showed unexpected benefits in reducing appetite and promoting weight loss. Researchers noticed that patients taking GLP-1-based treatments reported feeling fuller longer and experiencing fewer hunger cravings. This dual mechanism—better blood sugar management combined with natural appetite suppression—positioned GLP-1 as a breakthrough approach to metabolic health.

The pharmaceutical industry invested heavily in developing stable, injectable versions of GLP-1 that could mimic the hormone's effects in the human body. These synthetic compounds needed to withstand stomach acid, maintain effectiveness longer than natural GLP-1, and deliver results with minimal side effects. This developmental challenge took over a decade to solve before the first GLP-1 medication reached patients.

FDA Milestones: When GLP-1 Medications Entered the Market

Byetta (exenatide), a GLP-1 receptor agonist, became the first medication in this class to receive FDA approval in April 2005. The approval specifically targeted type 2 diabetes management, not weight loss, marking the beginning of GLP-1's clinical presence in American pharmacies. Byetta's introduction demonstrated that synthetic GLP-1 compounds could work safely and effectively in human patients, though adoption remained limited to diabetes specialists initially.

The landscape shifted significantly when Saxenda (liraglutide), a longer-acting GLP-1 agonist, received FDA approval in December 2014 as a weight management medication. Saxenda represented the first time the FDA explicitly approved a GLP-1 compound for obesity treatment in non-diabetic patients, signaling regulatory recognition of weight loss benefits. This approval broadened the potential patient population and began generating significant media attention, though mainstream awareness remained modest.

Wegovy (semaglutide), approved by the FDA in June 2021, marked the turning point in GLP-1 popularity. The STEP clinical trials showed semaglutide produced average weight losses of 15 percent or more in obese patients, rivaling results from weight loss surgery without the surgical risks. Media coverage exploded, celebrity endorsements amplified public interest, and Wegovy became the fastest-growing weight loss medication in pharmaceutical history.

How GLP-1 Medications Work: The Science Behind Weight Loss

GLP-1 receptor agonists function by mimicking a hormone your body naturally produces when you eat. These medications bind to GLP-1 receptors in the brain, specifically in areas controlling hunger, satiety, and food reward processing. By activating these receptors, GLP-1 medications effectively reset the appetite thermostat, making patients feel satisfied with smaller meals and experiencing fewer cravings throughout the day.

Beyond appetite suppression, GLP-1 medications slow stomach emptying—the rate at which food moves from the stomach into the small intestine. This delayed gastric emptying extends feelings of fullness after meals, naturally reducing overall calorie intake without requiring conscious restriction. Additionally, GLP-1 medications improve insulin secretion and enhance glucose control, supporting metabolic health even in non-diabetic patients.

Tirzepatide compounds, like those offered through PlexusDx, activate both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual activation amplifies weight loss effects and metabolic improvements compared to GLP-1-only medications. The combination creates what researchers call a synergistic effect—the two pathways working together produce greater results than either pathway alone.

The Explosion of GLP-1 Popularity: From 2021 Onward

Following Wegovy's approval in 2021, GLP-1 medications transitioned from specialty pharmaceuticals to household names within three years. Online searches for GLP-1 increased over 500 percent between 2021 and 2023, driven by celebrity adoption, social media discussions, and mainstream news coverage. Insurance companies reported handling unprecedented demand, creating shortages that lasted into 2024 as manufacturing struggled to meet global demand.

The popularity surge reflected a fundamental shift in how society viewed weight management—moving from willpower-focused narratives toward recognition of biological hormonal factors. Medical professionals acknowledged that obesity involves complex neurological and metabolic mechanisms, not merely lack of discipline. This paradigm shift legitimized pharmaceutical approaches to weight loss, attracting millions of patients who had previously viewed medications as failures or moral compromises.

Access models evolved rapidly to meet demand surges. PlexusDx emerged as a precision health company offering compounded semaglutide from licensed 503A compounding pharmacies starting at $179 monthly, alongside tirzepatide options from $229 monthly. These models made GLP-1 therapy accessible to patients without insurance, no membership fees required, while HSA/FSA eligibility broadened financial accessibility further. The availability of compounded medications from licensed facilities dramatically expanded GLP-1 access beyond traditional insurance-dependent pathways.

Choosing Your GLP-1 Option: PlexusDx Precision Approaches

Understanding why GLP-1 medications exploded in popularity requires recognizing their genuine efficacy—the STEP trials demonstrated semaglutide's ability to produce average weight losses exceeding 15 percent, while SURMOUNT trials showed tirzepatide achieving losses over 22 percent in some populations. These results substantially outperformed previous weight loss medications and generated enthusiasm among patients, physicians, and researchers alike.

PlexusDx offers multiple GLP-1 options tailored to individual needs and genetic predispositions. Compounded Semaglutide Injection ranges from $149 monthly, Oral Semaglutide begins at $209 monthly, Compounded Tirzepatide Injection spans $249 monthly, and Oral Tirzepatide ranges from $279 monthly. The Microdose GLP-1 Protocol offers an entry point at $129 monthly for patients starting their weight loss journey, while GLP-Squared represents the dual-mechanism innovation at $249 monthly.

The Precision Peptide Genetic Test ($99 add-on or $298 standalone) identifies your individual predispositions across 14 pathways, 49 peptides, and 150+ genetic insights. This genetic roadmap reveals which medication class—GLP-1 only, dual GLP-1/GIP, or microdose protocols—aligns with your biological makeup. All PlexusDx medications come from licensed 503A compounding pharmacies, serving all 50 states without insurance requirements, and qualify for HSA/FSA accounts.

Frequently Asked Questions About The Rise of GLP-1 Medications: When Did They Become Popular?

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.